Published in Biologics on July 13, 2009
Pegylated IFN-α sensitizes melanoma cells to chemotherapy and causes premature senescence in endothelial cells by IRF-1 mediated signaling. Cell Death Dis (2010) 0.78
RUNX1-ETO induces a type I interferon response which negatively effects t(8;21)-induced increased self-renewal and leukemia development. Leuk Lymphoma (2013) 0.75
Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science (1994) 26.02
How cells respond to interferons. Annu Rev Biochem (1998) 24.27
Toll-like receptor control of the adaptive immune responses. Nat Immunol (2004) 19.15
STATs and gene regulation. Science (1997) 16.55
Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci (1957) 13.46
Cellular responses to interferon-gamma. Annu Rev Immunol (1997) 13.23
Antiviral actions of interferons. Clin Microbiol Rev (2001) 13.06
Interferon-gamma: an overview of signals, mechanisms and functions. J Leukoc Biol (2003) 12.34
IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nat Immunol (2002) 11.87
Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat Rev Immunol (2005) 11.57
The nature of the principal type 1 interferon-producing cells in human blood. Science (1999) 10.90
Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol (2000) 9.70
Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol (2001) 9.68
Interferon-inducible antiviral effectors. Nat Rev Immunol (2008) 9.68
Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68
Plasmacytoid dendritic cells in immunity. Nat Immunol (2004) 9.11
Interferons and their actions. Annu Rev Biochem (1987) 8.36
Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat Med (1999) 8.01
Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A (1998) 6.82
Interferons, interferon-like cytokines, and their receptors. Immunol Rev (2004) 6.21
Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor. Science (1992) 6.09
Cutting edge: Cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol (1999) 5.86
Activation of transcription by IFN-gamma: tyrosine phosphorylation of a 91-kD DNA binding protein. Science (1992) 5.71
A road map for those who don't know JAK-STAT. Science (2002) 5.67
The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu Rev Immunol (1997) 4.76
Reciprocal regulation of polarized cytokine production by effector B and T cells. Nat Immunol (2000) 4.73
High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60
Prognostic significance of autoimmunity during treatment of melanoma with interferon. N Engl J Med (2006) 4.47
A critical function for type I interferons in cancer immunoediting. Nat Immunol (2005) 4.14
The proteins of ISGF-3, the interferon alpha-induced transcriptional activator, define a gene family involved in signal transduction. Proc Natl Acad Sci U S A (1992) 3.74
Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial. Lancet (2008) 3.62
The interferon system. A bird's eye view of its biochemistry. J Biol Chem (1992) 3.39
cDNA structures and regulation of two interferon-induced human Mx proteins. Mol Cell Biol (1989) 3.20
A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology (2001) 3.02
Cytokine therapeutics: lessons from interferon alpha. Proc Natl Acad Sci U S A (1994) 2.90
Host gene influences sensitivity to interferon action selectively for influenza virus. Nature (1980) 2.88
Regulation of cytokine signaling and inflammation. Cytokine Growth Factor Rev (2002) 2.69
The interferons. Mechanisms of action and clinical applications. JAMA (1991) 2.68
Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol (1983) 2.65
Vaccinia virus-encoded eIF-2 alpha homolog abrogates the antiviral effect of interferon. Virology (1991) 2.63
In breast carcinoma tissue, immature dendritic cells reside within the tumor, whereas mature dendritic cells are located in peritumoral areas. J Exp Med (1999) 2.54
Interferon-induced mx proteins: dynamin-like GTPases with antiviral activity. Traffic (2002) 2.44
A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res (2004) 2.28
Plasmacytoid dendritic cells: linking innate and adaptive immunity. J Virol (2005) 2.28
Immune interferon enhances functional properties of human granulocytes: role of Fc receptors and effect of lymphotoxin, tumor necrosis factor, and granulocyte-macrophage colony-stimulating factor. J Immunol (1987) 2.24
Multiplex analysis of serum cytokines in melanoma patients treated with interferon-alpha2b. Clin Cancer Res (2007) 2.15
IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol (2001) 2.13
p38 MAP kinase is required for STAT1 serine phosphorylation and transcriptional activation induced by interferons. EMBO J (1999) 2.07
Interferon-alpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood (1999) 1.97
Activation of the p38 mitogen-activated protein kinase by type I interferons. J Biol Chem (1999) 1.94
Plasmacytoid dendritic cells induce NK cell-dependent, tumor antigen-specific T cell cross-priming and tumor regression in mice. J Clin Invest (2008) 1.91
Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma. PLoS Med (2007) 1.89
Three-dimensional structure of recombinant human interferon-gamma. Science (1991) 1.88
The Janus protein tyrosine kinase family and its role in cytokine signaling. Adv Immunol (1995) 1.72
The antiviral state induced by alpha interferon and gamma interferon requires transcriptionally active Stat1 protein. J Virol (1996) 1.63
Requirement for HLA-DR+ accessory cells in natural killing of cytomegalovirus-infected fibroblasts. J Exp Med (1986) 1.63
Induction of MxA gene expression by influenza A virus requires type I or type III interferon signaling. J Virol (2007) 1.58
Interferons: mechanisms of action and clinical applications. Curr Opin Oncol (2003) 1.56
Interferon nomenclature. Nature (1980) 1.53
Recruitment of immature plasmacytoid dendritic cells (plasmacytoid monocytes) and myeloid dendritic cells in primary cutaneous melanomas. J Pathol (2003) 1.53
What is new in the treatment of multiple sclerosis? Drugs (2000) 1.46
Interferon-kappa, a novel type I interferon expressed in human keratinocytes. J Biol Chem (2001) 1.45
A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology (2000) 1.44
Structure and expression of human IFN-alpha genes. Philos Trans R Soc Lond B Biol Sci (1982) 1.33
The antiviral effects of the interferons and their inhibition. J Interferon Res (1992) 1.31
Interferon-alpha engages the insulin receptor substrate-1 to associate with the phosphatidylinositol 3'-kinase. J Biol Chem (1995) 1.31
Temozolomide in combination with interferon-alfa versus temozolomide alone in patients with advanced metastatic melanoma: a randomized, phase III, multicenter study from the Dermatologic Cooperative Oncology Group. J Clin Oncol (2005) 1.27
Pharmacokinetics of peginterferons. Semin Liver Dis (2003) 1.23
Role of p38alpha Map kinase in Type I interferon signaling. J Biol Chem (2003) 1.23
Interferon-mediated fatigue. Cancer (2001) 1.14
Interferon tau: a novel pregnancy recognition signal. Am J Reprod Immunol (1997) 1.14
Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. Blood (2002) 1.13
The human interferon alpha species and receptors. Biopolymers (2000) 1.11
Activation of different Stat5 isoforms contributes to cell-type-restricted signaling in response to interferons. Mol Cell Biol (1996) 1.07
Recruitment of Stat4 to the human interferon-alpha/beta receptor requires activated Stat2. J Biol Chem (2000) 1.05
Practical guidelines for the management of interferon-alpha-2b side effects in patients receiving adjuvant treatment for melanoma: expert opinion. Cancer (2008) 1.03
The type-I interferon receptor. The long and short of it. Cytokine Growth Factor Rev (1996) 1.01
Trophoblast interferons. Placenta (1999) 1.01
Diversity and relatedness among the type I interferons. J Interferon Cytokine Res (2004) 1.01
Autocrine secretion of interferon gamma negatively regulates homing of immature B cells. J Exp Med (2000) 0.98
Randomized dose-escalation study evaluating peginterferon alfa-2a in patients with metastatic malignant melanoma. J Clin Oncol (2006) 0.95
Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1. Mult Scler (2006) 0.95
Updated Swiss guidelines for the treatment and follow-up of cutaneous melanoma. Dermatology (2005) 0.95
Interferon-alpha activates signal transducers and activators of transcription 5 and 6 in Daudi cells. Eur J Biochem (1998) 0.94
Growth regulation of melanoma cells by interferon and (2'-5')oligoadenylate synthetase. Mol Cell Biol (1983) 0.92
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG). Ann Oncol (2008) 0.91
Phase II study of temozolomide plus pegylated interferon-alpha-2b for metastatic melanoma. Cancer (2006) 0.91
The human interferon-alpha species and hybrid proteins. Semin Oncol (1997) 0.90
Interferon treatment of renal cell carcinoma. Current status and future prospects. Cancer (1987) 0.89
Successful treatment of advanced hepatocellular carcinoma by combined administration of 5-fluorouracil and pegylated interferon-alpha. World J Gastroenterol (2005) 0.86
The type I interferon receptor mediates tyrosine phosphorylation of the CrkL adaptor protein. J Biol Chem (1997) 0.86
Identification of the major positional isomer of pegylated interferon alpha-2b. Biochemistry (2000) 0.86
Enhancement of antiproliferative activity of interferons by RNA interference-mediated silencing of SOCS gene expression in tumor cells. Cancer Sci (2008) 0.85
Nitric oxide and neopterin levels and clinical response in stage III melanoma patients receiving concurrent biochemotherapy. Melanoma Res (1998) 0.85
Interferon alpha but not interleukin 12 activates STAT4 signaling in human vascular endothelial cells. J Biol Chem (2004) 0.82
Melanoma after laser therapy of pigmented lesions--circumstances and outcome. Eur J Dermatol (2010) 0.99
Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching? Melanoma Res (2017) 0.76